What is the future of dementia research?
In July, London hosted the Alzheimer’s Association International Conference (AAIC), an annual conference dedicated to advancing dementia science and clinical practice.
How a clinical trial helped Paul find hope again
At just 56, Paul Norman from Whitchurch in Bristol began experiencing worrying changes in his memory and cognitive processing. Everyday tasks that had once been second nature became difficult. He struggled to manage aspects of his work and home life, and even his familiar commuting routes across Bristol started to feel completely unfamiliar. Paul shares his story of how volunteering for a clinical trial restored hope for his future.
READ-OUT study’s 1000th participant recruited at ReMind UK
Bob became the 1,000th volunteer to join the READ-OUT trial, an important milestone that shows the difference people can make by taking part in clinical research. After being diagnosed with mild cognitive impairment (MCI), he chose to take part in the READ-OUT trial, a major national dementia research study exploring whether blood tests could help diagnose dementia earlier and more accurately. Bob said that if his experience could help others facing the same uncertainty, it was worth it.
Why the conversation around anti-amyloid therapies matters
Recent headlines have reignited debate around anti-amyloid therapies for Alzheimer’s disease, following commentary around a review questioning whether these treatments provide meaningful benefit for people living with dementia. ReMind UK’s Research & Medical Director, Dr Tomas Welsh, responds to the debate.
How dementia research is making a real difference for carers: John’s story
When John Desmond’s wife, Linda, was diagnosed with semantic dementia in 2021 at the age of 67, it marked the beginning of a new chapter for them both. Semantic dementia, a form of frontotemporal dementia, affects a person’s ability to use and understand words.
Transforming dementia diagnosis through blood test research
A recent BBC News article highlights a groundbreaking trial exploring how new and existing blood tests could transform the way dementia is diagnosed in the UK.